Cost savings associated with timely treatment of botulism with botulism antitoxin heptavalent product
2019
Background
Botulism is a rare, serious, and sometimes fatal paralytic illness caused by exposure to neurotoxins produced by Clostridium botulinum bacteria. Patients with documented or suspected exposure to botulinum toxin serotypes A-G can be treated with BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)–(Equine)] product, which was approved in 2013 in the United States (US). Patients with botulism have demonstrated greater clinical benefit with early BAT product treatment (≤2 days from symptom onset) versus late treatment (>2 days).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
16
References
3
Citations
NaN
KQI